JP2003518510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003518510A5 JP2003518510A5 JP2001548149A JP2001548149A JP2003518510A5 JP 2003518510 A5 JP2003518510 A5 JP 2003518510A5 JP 2001548149 A JP2001548149 A JP 2001548149A JP 2001548149 A JP2001548149 A JP 2001548149A JP 2003518510 A5 JP2003518510 A5 JP 2003518510A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- dna
- hyaluronic acid
- purified hyaluronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 30
- 229920002674 hyaluronan Polymers 0.000 description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 16
- 229960003160 hyaluronic acid Drugs 0.000 description 16
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 241000187481 Mycobacterium phlei Species 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940055036 mycobacterium phlei Drugs 0.000 description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000030381 cutaneous melanoma Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 201000003708 skin melanoma Diseases 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17337599P | 1999-12-28 | 1999-12-28 | |
| US60/173,375 | 1999-12-28 | ||
| PCT/CA2000/001562 WO2001047561A1 (en) | 1999-12-28 | 2000-12-28 | Hyaluronic acid in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003518510A JP2003518510A (ja) | 2003-06-10 |
| JP2003518510A5 true JP2003518510A5 (enExample) | 2008-05-29 |
| JP4215429B2 JP4215429B2 (ja) | 2009-01-28 |
Family
ID=22631719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001548149A Expired - Fee Related JP4215429B2 (ja) | 1999-12-28 | 2000-12-28 | 癌治療におけるヒアルロン酸 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7125858B2 (enExample) |
| EP (1) | EP1250152B1 (enExample) |
| JP (1) | JP4215429B2 (enExample) |
| AU (1) | AU784356B2 (enExample) |
| CA (1) | CA2395493C (enExample) |
| DK (1) | DK1250152T3 (enExample) |
| NZ (1) | NZ520312A (enExample) |
| WO (1) | WO2001047561A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60036915T2 (de) | 1999-01-13 | 2008-08-07 | Alchemia Oncology Pty Ltd., Hawthorn | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln |
| PT1238070E (pt) * | 1999-12-13 | 2007-11-06 | Bioniche Life Sciences Inc | Oligonucleótidos sintéticos úteis sob o ponto de vista terapêutico |
| US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| US8039602B2 (en) | 2000-10-31 | 2011-10-18 | Ryogen Llc | Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 |
| US7087586B2 (en) * | 2001-04-24 | 2006-08-08 | Bioniche Life Sciences, Inc. | Oligonucleotide compositions and their use to induce differentiation of cells |
| ITPD20020271A1 (it) | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| JP4851185B2 (ja) | 2003-05-16 | 2012-01-11 | ジェレックスインターナショナル株式会社 | アレルギー症状抑制剤及び空気濾過フィルター |
| US20060240084A1 (en) * | 2005-04-20 | 2006-10-26 | Xylos Corporation | Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use |
| AU2006274509B2 (en) * | 2005-07-27 | 2012-01-19 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| CN101287475B (zh) * | 2005-09-07 | 2012-11-14 | 阿尔卡米亚肿瘤学股份有限公司 | 包含透明质酸和治疗抗体的治疗组合物以及制药用途 |
| WO2008070538A2 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
| DE102009035586A1 (de) | 2009-07-31 | 2011-02-03 | Fresenius Kabi Deutschland Gmbh | Intravesikale Instillationslösungen zur Behandlung von Blasenkrebs |
| KR101802540B1 (ko) | 2009-09-25 | 2017-11-28 | 큐알엔에이, 인크. | Ｆｌｇ의 발현 및 활성을 조절함으로써 필라그린(ｆｌｇ)에 관련된 질환의 치료 |
| AU2011315093B2 (en) | 2010-10-13 | 2013-10-17 | Telesta Therapeutics Ip Inc. | Bacterial ribonucleic acid cell wall compositions and methods of making and using them |
| EP3044614A1 (en) * | 2013-09-12 | 2016-07-20 | DSM IP Assets B.V. | Ocular device |
| EP3541358A1 (en) | 2016-11-21 | 2019-09-25 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| WO2020252003A1 (en) | 2019-06-13 | 2020-12-17 | Hollister Incorporated | Reusable urinary catheter products |
| US12440644B2 (en) | 2019-06-25 | 2025-10-14 | Hollister Incorporated | Reusable urinary catheter products |
| US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
| JP7500038B2 (ja) * | 2019-08-27 | 2024-06-17 | 国立研究開発法人物質・材料研究機構 | 炎症性サイトカイン産生抑制材、ヒアルロン酸誘導体、及び、ヒアルロン酸誘導体の製造方法。 |
| CN115776909A (zh) * | 2020-07-17 | 2023-03-10 | 美国杰龙生物医药公司 | 皮下端粒酶抑制剂组合物及其使用方法 |
| US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172815A (en) * | 1962-04-24 | 1965-03-09 | Warner Lambert Pharmaceutical | Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof |
| FR2160326B1 (enExample) * | 1971-11-19 | 1975-02-07 | Anvar | |
| US4152423A (en) * | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
| CH602920A5 (enExample) * | 1973-02-23 | 1978-08-15 | Wellcome Found | |
| US3976544A (en) * | 1973-06-19 | 1976-08-24 | The Agence Nationale De Valorisation De Le Recherche | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction |
| FR2374042A1 (fr) * | 1976-06-04 | 1978-07-13 | Merieux Inst | Nouveau medicament immunostimulant et son procede de preparation |
| JPS54140710A (en) * | 1978-03-10 | 1979-11-01 | Mitsui Toatsu Chem Inc | Anti-tumor substance and its preparation |
| DE3011461C2 (de) * | 1980-03-25 | 1986-10-30 | Dr. Madaus & Co, 5000 Köln | Verwendung von Propionibakterien |
| US4520019A (en) * | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4579941A (en) * | 1982-08-13 | 1986-04-01 | Mitsuitoatsu Chemicals, Inc. | Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent |
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| GB8404280D0 (en) * | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
| DE3408768A1 (de) | 1984-03-09 | 1985-09-12 | Bayer Ag, 5090 Leverkusen | Immunstimulierende mittel |
| US4744984A (en) * | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| JPH0725683B2 (ja) | 1985-10-31 | 1995-03-22 | ザ オ−ストラリアン ナシヨナル ユニバ−シテイ− | 免疫治療方法 |
| US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4837202A (en) | 1987-09-14 | 1989-06-06 | Pitman-Moore, Inc. | Method for stimulating the immune system |
| DE3818054C2 (de) | 1988-05-27 | 1994-02-17 | Biotest Pharma Gmbh | Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| WO1998017320A1 (en) | 1991-07-03 | 1998-04-30 | Hyal Pharmaceutical Corporation | Use of hyaluronan in gene therapy |
| CA2122519C (en) | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| AU691797B2 (en) | 1993-01-29 | 1998-05-28 | Vetrepharm, Inc. | Immunotherapeutic composition |
| AU6362594A (en) * | 1993-03-10 | 1994-09-26 | Miles Inc. | Hyaluronic acid used as a cancer treatment |
| IN181358B (enExample) * | 1995-02-14 | 1998-05-30 | Bioniche Inc | |
| WO1997033612A1 (en) | 1996-03-15 | 1997-09-18 | Immunotherapy, Inc. | Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases |
| CA2208924A1 (en) | 1997-07-09 | 1999-01-09 | Hyal Pharmaceutical Corporation | Sparing paclitaxel by the use of hyaluronan |
| JP4335435B2 (ja) * | 1997-08-05 | 2009-09-30 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | 細胞増殖および細胞死を調節する組成物および方法 |
| DE69829316T2 (de) | 1998-02-18 | 2006-04-13 | Bioniche Life Sciences Inc., Belleville | Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand |
| WO2000033875A1 (en) | 1998-12-04 | 2000-06-15 | Bioniche Life Sciences Inc. | Chemotherapeutic composition and method |
| DE60036915T2 (de) | 1999-01-13 | 2008-08-07 | Alchemia Oncology Pty Ltd., Hawthorn | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln |
| CA2266188A1 (en) | 1999-03-19 | 2000-09-19 | Stephen Chizick | Natural preparation for treatment of male pattern hair loss |
-
2000
- 2000-12-28 EP EP00986939.7A patent/EP1250152B1/en not_active Expired - Lifetime
- 2000-12-28 CA CA2395493A patent/CA2395493C/en not_active Expired - Fee Related
- 2000-12-28 DK DK00986939.7T patent/DK1250152T3/da active
- 2000-12-28 US US10/168,327 patent/US7125858B2/en not_active Expired - Fee Related
- 2000-12-28 JP JP2001548149A patent/JP4215429B2/ja not_active Expired - Fee Related
- 2000-12-28 NZ NZ520312A patent/NZ520312A/en not_active IP Right Cessation
- 2000-12-28 AU AU23364/01A patent/AU784356B2/en not_active Ceased
- 2000-12-28 WO PCT/CA2000/001562 patent/WO2001047561A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Takakura et al. | Enhanced lymphatic delivery of mitomycin C conjugated with dextran | |
| Hatefi et al. | Camptothecin delivery methods | |
| Kabanov et al. | Pluronic® block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers | |
| Rosato et al. | HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer | |
| US7125858B2 (en) | Hyaluronic acid in the treatment of cancer | |
| Zhang et al. | Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma | |
| ES2235839T3 (es) | Uso de oligonucleotidos estabilizados para la preparacion de un medicamento de accion antitumoral. | |
| EP0695169A1 (en) | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use | |
| CN101098684A (zh) | 自由基疾病预防治疗用组合物 | |
| TW201228661A (en) | Pharmaceutical composition for treating brain cancer or reducing temozolomide-resistance of brain cancer cells and uses of the same | |
| Quan et al. | Synthesis of PEGylated hyaluronic acid for loading dichloro (1, 2-diaminocyclohexane) platinum (II)(DACHPt) in nanoparticles for cancer treatment | |
| JPS6388128A (ja) | 腫瘍細胞転移抑制剤 | |
| AU2021202582B2 (en) | Nanoparticles for use as a therapeutic vaccine | |
| US20160361268A1 (en) | Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis | |
| Tang et al. | Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin | |
| LI et al. | Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers: pharmacokinetics and anti-tumor effects | |
| JP6223995B2 (ja) | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 | |
| WO2023166511A1 (en) | Ionizable lipids and compositions comprising same | |
| JP2004502789A5 (enExample) | ||
| Miyazaki et al. | Preparation and Evaluation in Vitro and in Vivo of Fibrinogen Micropheres Containing Adrinamycin | |
| Mizuno et al. | Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice | |
| WO2006069344A2 (en) | Controlled release hydrogels | |
| CN114557988A (zh) | 苄索氯铵在制备抑制结直肠癌转移药物方面的应用 | |
| CN117137884B (zh) | 基于细菌细胞膜的纳米药物组合物及其制备方法与应用 | |
| JP2007531697A (ja) | 疎水性薬剤のデリバリーのための組成物と方法 |